Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US OptionsDetailed Quotes
LYEL250516P2000
- 0.00
- 0.000.00%
15min DelayClose May 2 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-333.84%PremiumMay 16, 2025Expiry Date1.54Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Lyell Immunopharma Newsroom
H.C. Wainwright Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $1
Lyell Immunopharma Analyst Ratings
BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating
Bank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)
H.C. Wainwright Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $1
Analysts Conflicted on These Healthcare Names: Electrocore (ECOR), Viking Therapeutics (VKTX) and Lyell Immunopharma (LYEL)
Lyell Immunopharma Analyst Ratings
BofA Securities Downgrades Lyell Immunopharma(LYEL.US) to Sell Rating, Cuts Target Price to $0.6
Bank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)
Morgan Stanley Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $4
Lyell Immunopharma Analyst Ratings
Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges
Lyell Immunopharma Cut to Underperform From Buy by B of A Securities
Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.
Lyell Immunopharma Analyst Ratings
H.C. Wainwright Downgrades Lyell Immunopharma(LYEL.US) to Hold Rating, Cuts Target Price to $1
Neutral Rating for Lyell Immunopharma Amid Strategic Shifts and Competitive Challenges
Lyell Immunopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Lyell Immunopharma (LYEL) and Janux Therapeutics Inc (JANX)
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
